Drug Discovery Targeting Drug Resistant Bacteria

Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included. Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful. Written by scientists with extensive industrial experience in drug discovery Provides a balanced view of the field, including its challenges and future directions Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war

This book compiles the latest information in the field of antibacterial discovery, especially with regard to the looming threat of multi-drug resistance. The respective chapters highlight the discovery of new antibacterial and anti-infective compounds derived from microbes, plants, and other natural sources. The potential applications of nanotechnology to the fields of antibacterial discovery and drug delivery are also discussed, and one section of the book is dedicated to the use of computational tools and metagenomics in antibiotic drug discovery. Techniques for efficient drug delivery are also covered. The book provides a comprehensive overview of the progress made in both antibacterial discovery and delivery, making it a valuable resource for academic researchers, as well as those working in the pharmaceutical industry.

The rise in the incidence of infections is caused by multi drugresistant (MDR) bacteria, it is essential to elucidate the basic mechanism ofantibiotic resistance to discover effective methods for diagnosis and treatmentof infections. The use of pathogen-specific probes offers a faster alternative forpathogen detection and could improve the diagnosis of infection. High resolutionmelting analysis techniques are useful for the detection of multi drugresistant pathogens. Rational Structural Based Drug Design is a common methodto identify a lead compound and take it forward for further developments.This book provides information about recent strategies involved in thediagnosis and treatment of infections caused by MDR bacteria. The volume coversthe use of molecular probes for the quantification of pathogenic bacteria, alongwith other techniques mentioned above. Chapters also cover the use of identificationof novel drug targets from the Lipid A biosynthesis and also from quorum sensingmediated biofilm formation in MDR bacteria. Chapters also cover herbal alternatives for the treatment of MDRbacteria like the use of Cassiaaungustifolia in treatment of various diseases. The reference is suitablefor biomedical students, cellular and molecular biologists.

Recent years have seen a resurgence of antibiotic drug discovery. This book brings together the relevant information to assess the state-of-the-art. It identifies and elaborates the most recent and compelling strategies for antibiotic drug discovery with a primary focus on new targets, mechanisms and molecular entities. Addressing the need for continued investment in antibiotic drug development, the book provides a point of reference for the rapidly expanding infectious disease research community. In addition to its attention on new targets, the book focusses on the medicinal chemistry and chemistry of the targets. Within this framework, chapters from leading researchers in academia and industry address findings in important areas such as biofilm production, narrow spectrum antibiotics and novel antibacterials from previously uncultured soil bacteria. This book will be a useful resource for postgraduate students and researchers in medicinal chemistry wishing to understand the latest approaches to antibiotic drug discovery.

This eBook series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the eBook series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The fourth volume of this series features 5 chapters that cover the following topics: - An overview of the incidence of neuraminadase resistance in influenza viruses in the Americas from 2004 to 2014 - Phenothiazines and derivative compounds for treating Trypanosoma cruzi infections - New antibacterial drug targets such as polysaccharide deacetylases - Improvements in aminoglycoside synthesis and biological activity (including RNA targeting) - A review of new chemotherapeutic agents against common infections.

According to the World Health Organization, antimicrobial resistance is a major threat to global health because the number of alternative antibiotics is very limited. Antimicrobial resistance is a slow evolutionary process that has been accelerated by human activities in health, environment and agriculture sectors. Due to their wide application, antibiotics and their residues have been found in almost all food products and natural ecosystems. This book reviews the drivers, impact and mitigation of antimicrobial resistance, with focus on methods and targets.

Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.

This book summarizes the emerging trends in the field of antibiotic resistance of various gram-negative and gram-positive bacterial species. The ability of different species of bacteria to resist the antimicrobial agent has become a global problem. As such, the book provides a comprehensive overview of the advances in our understanding of the origin and mechanism of resistance, discusses the modern concept of the biochemical and genetic basis of antibacterial resistance and highlights the clinical and economic implications of the increased prevalence of antimicrobial resistant pathogens and their ecotoxic effects. It also reviews various strategies to curtail the emergence and examines a number of innovative therapeutic approaches, such as CRISPR, phage therapy, nanoparticles and natural antimicrobials, to combat the spread of resistance.